The link between benign prostatic hyperplasia and prostate cancer

Nature Reviews Urology

Volumn 10, Issue 1, 2013, Pages 49-54

  Ørsted, David D ^a   Bojesen, Stig E ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TAMSULOSIN;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CHRONIC INFLAMMATION; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; GENETIC VARIABILITY; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; RISK REDUCTION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84871918357     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.192     Document Type: Review

References (77)

1. Sommers, S. C. Endocrine changes with prostatic carcinoma. Cancer 10, 345-358 (1957)
2. Orsted, D. D., Bojesen, S. E., Nielsen, S. F. & Nordestgaard, B. G. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur. Urol. 60, 691-698 (2011)
3. Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010)
4. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012)
5. McVary, K. T. BPH: epidemiology and comorbidities. Am. J. Manag. Care 12, S122-S128 (2006)
6. Roehrborn, C. G. & Black, L. K. The economic burden of prostate cancer. BJU Int. 108, 806-813 (2011)
7. Lepor, H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev. Urol. 6 (Suppl. 9), S3-S10 (2004)
8. Alcaraz, A., Hammerer, P., Tubaro, A., Schroder, F. H. & Castro, R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur. Urol. 55, 864-873 (2009)
9. Guess, H. A. Benign prostatic hyperplasia and prostate cancer. Epidemiol. Rev. 23, 152-158 (2001)
10. Nickel, J. C. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 54, 1379-1384 (2008)
11. Montironi, R., Mazzucchelli, R., Lopez-Beltran, A., Scarpelli, M. & Cheng, L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int. 108, 1394-1401 (2011)
12. Davidsson, S. et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2280-2287 (2011)
13. Merrimen, J. L. et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J. Urol. 182, 485-490 (2009)
14. De Marzo, A. M., Nelson, W. G., Bieberich, C. J. & Yegnasubramanian, S. Prostate cancer: new answers prompt new questions regarding cell of origin. Nat. Rev. Urol. 7, 650-652 (2010)
15. Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362, 1192-1202 (2010)
16. Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215-224 (2003)
17. De Nunzio, C. et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur. Urol. 60, 106-117 (2011)
18. De Nunzio, C., Aronson, W., Freedland, S. J., Giovannucci, E. & Parsons, J. K. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 61, 560-570 (2012)
19. Chokkalingam, A. P. et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer 98, 1727-1734 (2003)
20. Bostwick, D. G. et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70, 291-301 (1992)
21. Armenian, H. K., Lilienfeld, A. M., Diamond, E. L. & Bross, I. D. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet 2, 115-117 (1974)
22. Greenwald, P., Kirmss, V., Polan, A. K. & Dick, V. S. Cancer of the prostate among men with benign prostatic hyperplasia. J. Natl Cancer Inst. 53, 335-340 (1974)
23. Simons, B. D., Morrison, A. S., Young, R. H. & Verhoek-Oftedahl, W. The relation of surgery for prostatic hypertrophy to carcinoma of the prostate. Am. J. Epidemiol. 138, 294-300 (1993)
24. Schenk, J. M. et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am. J. Epidemiol. 173, 1419-1428 (2011)
25. Thompson, I. M., Coltman, C. A. Jr & Crowley, J. Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate 33, 217-221 (1997)
26. Jacobsen, S. J. et al. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology 45, 64-69 (1995)
27. Meigs, J. B. et al. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. Am. J. Med. 104, 517-525 (1998)
28. Allin, K. H., Bojesen, S. E. & Nordestgaard, B. G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27, 2217-2224 (2009)
29. Zacho, J. et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med. 359, 1897-1908 (2008)
30. De Marzo, A. M., Nakai, Y. & Nelson, W. G. Inflammation, atrophy, and prostate carcinogenesis. Urol. Oncol. 25, 398-400 (2007)
31. MacLennan, G. T. et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5year followup study. J. Urol. 176, 1012-1016 (2006)
32. Saito, K. & Kihara, K. C-reactive protein as a biomarker for urological cancers. Nat. Rev. Urol. 8, 659-666 (2011)
33. Meyer, M. S. et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 31, 1597-1603 (2010)
34. Beuten, J. et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol. Biomarkers Prev. 19, 588-599 (2010)
35. Merrimen, J. L., Jones, G. & Srigley, J. R. Is high grade prostatic intraepithelial neoplasia still a risk factor for adenocarcinoma in the era of extended biopsy sampling? Pathology 42, 325-329 (2010)
36. Mahmud, S. M. et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6, e16412 (2011)
37. Mahmud, S. M., Franco, E. L. & Aprikian, A. G. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 127, 1680-1691 (2010)
38. Roehrborn, C. G., Kaplan, S. A. & Noble, B. W. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J. Urol. 173, 364 (2005)
39. Robert, G. et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 69, 1774-1780 (2009)
40. Kramer, G., Mitteregger, D. & Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 51, 1202-1216 (2007)
41. Schauer, I. G. & Rowley, D. R. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 82, 200-210 (2011)
42. Schenk, J. M. et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 171, 571-582 (2010)
43. St. Sauver, J. L. et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am. J. Epidemiol. 169, 1281-1290 (2009)
44. Sutcliffe, S. et al. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 110, 1050-1059 (2012)
45. Roehrborn, C. G. et al. Baseline data from the Combination of Avodart and Tamsulosin (CombAT) trial: relationships between body mass index (BMI) and LUTS/BPH measures. Eur. Urol. Suppl. 5, 195 (2006)
46. Hammarsten, J. & Hogstedt, B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand. J. Urol. Nephrol. 36, 330-338 (2002)
47. Hammarsten, J. & Hogstedt, B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 39, 151-158 (2001)
48. Hammarsten, J. & Hogstedt, B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 8, 29-36 (1999)
49. Sarma, A. V. et al. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 31, 476-482 (2008)
50. McLaren, I. D., Jerde, T. J. & Bushman, W. Role of interleukins, IGF and stem cells in BPH. Differentiation 82, 237-243 (2011)
51. Nemesure, B., Wu, S. Y., Hennis, A. & Leske, M. C. Central adiposity and prostate cancer in a Black population. Cancer Epidemiol. Biomarkers Prev. 21, 851-858 (2012)
52. Wright, M. E. et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109, 675-684 (2007)
53. Andersson, S. O. et al. Body size and prostate cancer: a 20-year follow-up study among 135,006 Swedish construction workers. J. Natl Cancer Inst. 89, 385-389 (1997)
54. Dimitropoulou, P. et al. Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. Br. J. Cancer 104, 875-881 (2011)
55. Albanes, D. et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J. Natl Cancer Inst. 101, 1272-1279 (2009)
56. Hayashi, N. et al. The impact of hypertriglyceridemia on prostate cancer development in patients aged >/=60 years. BJU Int. 109, 515-519 (2012)
57. van Hemelrijck, M. et al. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 117, 2086-2095 (2011)
58. Yeh, H. C. et al. A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 35, 113-118 (2012)
59. Mantzoros, C. S. et al. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer 76, 1115-1118 (1997)
60. Rowlands, M. A. et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res. 72, 503-515 (2012)
61. Tindall, D. J. & Rittmaster, R. S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J. Urol. 179, 1235-1242 (2008)
62. Nacusi, L. P. & Tindall, D. J. Targeting 5alpha-reductase for prostate cancer prevention and treatment. Nat. Rev. Urol. 8, 378-384 (2011)
63. Gann, P. H. et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 26, 40-49 (1995)
64. St. Sauver, J. L. et al. Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. Am. J. Epidemiol. 173, 787-796 (2011)
65. Kristal, A. R. et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 168, 1416-1424 (2008)
66. Roddam, A. W., Allen, N. E., Appleby, P. & Key, T. J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170-183 (2008)
67. Morgentaler, A. & Traish, A. M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 55, 310-320 (2009)
68. Wurzel, R., Ray, P., Major-Walker, K., Shannon, J. & Rittmaster, R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 10, 149-154 (2007)
69. Zhu, Y. S. & Imperato-McGinley, J. L. 5alpha-reductase isozymes and androgen actions in the prostate. Ann. NY Acad. Sci. 1155, 43-56 (2009)
70. Balistreri, C. R., Caruso, C., Carruba, G., Miceli, V. & Candore, G. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study. OMICS 15, 369-374 (2011)
71. Klotsman, M., Weinberg, C. R., Davis, K., Binnie, C. G. & Hartmann, K. E. A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH. Pharmacogenomics J. 4, 251-259 (2004)
72. Mononen, N. et al. Androgen receptor CAG polymorphism and prostate cancer risk. Hum. Genet. 111, 166-171 (2002)
73. Tang, L. et al. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 32, 1500-1506 (2011)
74. Habuchi, T. et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 60, 5710-5713 (2000)
75. McIntyre, M. H. et al. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol. Biomarkers Prev. 16, 2233-2236 (2007)
76. Chae, Y. K., Huang, H. Y., Strickland, P., Hoffman, S. C. & Helzlsouer, K. Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS ONE 4, e6523 (2009)
77. Kote-Jarai, Z. et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 43, 785-791 (2011).